Myelodysplastic Syndrome Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the Myelodysplastic Syndrome market?
The market size for myelodysplastic syndrome has seen a swift expansion in the recent times. It is forecasted to rise from $2.56 billion in the year 2024 to around $2.85 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.3%. The impressive growth observed in the historic phase can be accredited to the escalating prevalence of myelodysplastic syndrome, enhanced consciousness regarding its treatment, increased expenditure on healthcare, and various government initiatives.
What will be the myelodysplastic syndrome market size in the future?
In the coming years, the market size of myelodysplastic syndrome is anticipated to experience robust growth and is projected to reach $4.17 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.0%. The expected growth during the forecast period can be attributed to factors such as the aging population, the use of combination therapies, investment in hematologic research, and personalized medicine. Key trends during the forecast period includes innovation in treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, and collaborative research.
Get your myelodysplastic syndrome market report here!
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report
What main drivers are fueling expansion in the myelodysplastic syndrome market?
The upsurge in rare blood cancer cases is projected to boost the myelodysplastic syndrome (MDS) market’s progress in the forthcoming period. Blood cancers, which have a minimal occurrence rate in the populace, are a form of hematologic malignancies stemming from bone marrow, lymph nodes, and other blood and immune system ingredients. The principal objective of myelodysplastic syndrome (MDS) treatment is to manage the illness by enhancing blood cell production and dealing with associated symptoms to hinder the growth of blood cancer in the bone marrow. For example, the Leukemia and Lymphoma Society, a US-based professional organization, states that every three minutes, someone in the US is diagnosed with leukemia, lymphoma, or myeloma. The anticipated number of people facing these cancers in 2024 is about 187,740, which equals 9.4% of the expected 2,001,140 new cancer cases in the US. Therefore, the escalating occurrence of blood cancer is driving the surge in the myelodysplastic syndrome (MDS) market. A likely increase in bone marrow transplants is set to fuel the growth of the myelodysplastic syndrome market. Bone marrow transplant is a procedure that substitutes damaged or diseased bone marrow with healthy stem cells to treat various disorders. MDS is characterized by bone marrow failure occurring due to the abnormal growth of somatically altered clonal hematopoietic stem cells. Bone marrow transplants can potentially cure MDS by replacing defected stem cells with healthy ones. As an illustration, the National Transplant Organization (ONT), an independent coordinating agency based in Spain, reported that Spain added 23,686 donors to the Spanish Bone Marrow Donor Registry in 2023, an 8% rise from 2022, and achieved an all-time high of 3,717 hematopoietic stem cell transplants, which comes down to 77.4 transplants per million population. Consequently, an increase in the number of bone marrow transplants is fueling the growth of the myelodysplastic syndrome market.
What key areas define the segmentation of the global myelodysplastic syndrome market?
The myelodysplastic syndrome market covered in this report is segmented –
1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia, Myelodysplastic Syndrome With Multilineage Dysplasia, Myelodysplastic Syndrome With Ring Sideroblasts, Other Types
2) By Drug: Azacitidine, Lenalidomide, Decitabine, Deferasirox
3) By Treatment: Supportive Therapy, Growth Factors, Chemotherapy, Stem Cell Transplant, Other Treatments
4) By Route Of Administration: Oral, Injectable, Other Routes Of Administrations
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Myelodysplastic Syndrome With Unilineage Dysplasia: Type Of Dysplasia, Patient Demographics
2) By Myelodysplastic Syndrome With Multilineage Dysplasia: Severity Of Dysplasia, Patient Demographics
3) By Myelodysplastic Syndrome With Ring Sideroblasts: Percentage Of Ring Sideroblasts, Treatment Options
4) By Other Types: Specific Types, Treatment Options
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12920&type=smp
Who are the dominant players expanding their reach in the myelodysplastic syndrome market?
Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.
How are evolving market trends shaping myelodysplastic syndrome Strategies?
Leading businesses in the myelodysplastic syndrome (MDS) market are innovating with new treatments to fortify their market stance. For instance, Bristol Myers Squibb, an American pharmaceutical company, received FDA approval in August 2023 for Reblozyl (luspatercept-aamt) as an initial therapy for anemia in ESA-naïve adults who have low to intermediate-risk myelodysplastic syndromes (MDS) and may require consistent RBC transfusions. The Phase 3 COMMANDS trial displayed superior effectiveness of Reblozyl in attaining RBC transfusion independence and boosting hemoglobin levels compared to epoetin alfa, thus addressing anemia in a more diversified patient pool at an earlier stage.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
Which regions are emerging as leaders in the myelodysplastic syndrome market?
North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Cancer Clinical Decision Tools Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Cancer Monoclonal Antibodies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodie-global-market-report
Chronic Lymphocytic Leukemia Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
